- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04173325
Feasibility and Safety Study of Nivolumab With Irinotecan for Small Cell Lung Cancer
June 10, 2022 updated by: Nagla Abdel Karim, Augusta University
Phase I Feasibility and Safety Study of Nivolumab in Combination With Irinotecan in Relapsed or Refractory Small Cell Lung Cancer (SCLC) Followed by Maintenance Nivolumab
This study will determine the frequency of adverse events (side effects) in patients with relapsed or refractory small cell lung cancer (SCLC) when given nivolumab and irinotecan together followed by nivolumab maintenance.
This study will test the safety of the study treatments when given together and see what effect (good or bad) it has on participants and their cancer.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
10
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Georgia
-
Augusta, Georgia, United States, 30912
- Georgia Cancer Center at AU Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Confirmed SCLC with known UGT1A genotype.
- Patients who have received at least 1 prior platinum-based chemotherapy.
- Life expectancy of 3 months or more.
- Measurable disease.
Exclusion Criteria:
- Patients with UGT1A polymorphism.
- Currently receiving chemotherapy.
- Pregnant and nursing women.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Nivolumab and Irinotecan
Drug: Nivolumab 360mg IV Day 1 of each 21 day cycle until disease progression or unacceptable toxicity + Drug: Irinotecan 500mg IV Day of each 21 day cycle for 2 cycles Followed by maintenance nivolumab (without irinotecan)
|
PD-1 inhibitor approved by the US FDA for treatment of patients with lung cancer.
Chemotherapy drug currently FDA approved for treatment of multiple tumors, including small cell lung cancer.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluate the frequency and severity of adverse events in patients with small cell lung cancer after receiving nivolumab plus irinotecan followed by nivolumab maintenance.
Time Frame: through study completion, an average of 1 year
|
CTCAE v.4.0.
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0.
|
through study completion, an average of 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall response rate
Time Frame: through study completion, an average of 1 year
|
Tumor response evaluation with RECIST
|
through study completion, an average of 1 year
|
Progression-free survival (PFS)
Time Frame: through study completion, an average of 1 year
|
PFS as measured from start of therapy till disease progression.
|
through study completion, an average of 1 year
|
Overall survival (OS)
Time Frame: through study completion, an average of 1 year.
|
OS as measured from start of therapy till date of death or last follow up assessment.
|
through study completion, an average of 1 year.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Nagla A Karim, MD, PhD, Augusta University Georgia Cancer Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 6, 2020
Primary Completion (Actual)
May 26, 2022
Study Completion (Actual)
May 26, 2022
Study Registration Dates
First Submitted
November 14, 2019
First Submitted That Met QC Criteria
November 20, 2019
First Posted (Actual)
November 21, 2019
Study Record Updates
Last Update Posted (Actual)
June 14, 2022
Last Update Submitted That Met QC Criteria
June 10, 2022
Last Verified
June 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Small Cell Lung Carcinoma
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Topoisomerase Inhibitors
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
- Topoisomerase I Inhibitors
- Nivolumab
- Irinotecan
Other Study ID Numbers
- GCC-20-009
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Small Cell Lung Carcinoma
-
National Cancer Institute (NCI)RecruitingExtensive Stage Lung Small Cell Carcinoma | Limited Stage Lung Small Cell Carcinoma | Platinum-Resistant Lung Small Cell Carcinoma | Platinum-Sensitive Lung Small Cell Carcinoma | Recurrent Lung Small Cell CarcinomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingExtensive Stage Lung Small Cell Carcinoma | Limited Stage Lung Small Cell Carcinoma | Platinum-Resistant Lung Small Cell Carcinoma | Platinum-Sensitive Lung Small Cell Carcinoma | Bladder Small Cell Neuroendocrine Carcinoma | Extrapulmonary Small Cell Neuroendocrine Carcinoma | Recurrent Lung... and other conditionsUnited States
-
National Cancer Institute (NCI)TerminatedExtensive Stage Lung Small Cell CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedCarcinoma, Non-Small Cell Lung | Carcinoma, Small-Cell LungUnited States
-
Ohio State University Comprehensive Cancer CenterNational Institute on Aging (NIA)RecruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Extensive Stage Lung Small Cell Carcinoma | Unresectable Lung Non-Small Cell Carcinoma | Advanced Lung Non-Small Cell Carcinoma | Advanced... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedStage IIIA Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
-
University of WashingtonNational Cancer Institute (NCI); Imago BioSciences, Inc., a subsidiary of Merck...SuspendedExtensive Stage Lung Small Cell Carcinoma | Limited Stage Lung Small Cell CarcinomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingPlatinum-Resistant Lung Small Cell Carcinoma | Platinum-Sensitive Lung Small Cell Carcinoma | Recurrent Extensive Stage Lung Small Cell Carcinoma | Refractory Extensive Stage Lung Small Cell CarcinomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingExtensive Stage Lung Small Cell CarcinomaUnited States
-
National Cancer Institute (NCI)TerminatedStage IIIA Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
Clinical Trials on Nivolumab 10 MG/ML Intravenous Solution [OPDIVO]
-
Sheba Medical CenterProf. Ronit Satchi-Fainaro, Director, Cancer Biology Research Center, Tel...RecruitingAdvanced Glioblastoma | MGMT-Unmethylated Glioblastoma | Metastatic Melanoma in the Central Nervous SystemIsrael
-
University Hospital, EssenRecruitingNSCLC, Stage I | NSCLC Stage II | NSCLC, Stage IIIABelgium, Germany, Netherlands
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Bristol-Myers SquibbWithdrawn
-
University Hospital, Strasbourg, FranceBristol-Myers SquibbCompleted
-
Universitair Ziekenhuis BrusselActive, not recruiting
-
Spanish Lung Cancer GroupCompletedNon Small Cell Lung CancerSpain
-
Hitendra PatelStand Up To Cancer; Lustgarten FoundationSuspendedPancreatic Cancer Stage IVUnited States
-
GERCOR - Multidisciplinary Oncology Cooperative...Bristol-Myers SquibbRecruitingLocalized Oesogastric Adenocarcimona | MSI and or dMMRFrance
-
Jules Bordet InstituteRecruitingRectal Cancer Stage II | Rectal Cancer Stage IIIBelgium, France
-
Bispebjerg HospitalUnknownImmune Response | Immunotherapy | BCC - Basal Cell Carcinoma | Ablative Fractionated LaserDenmark